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Background
The Aspergillus oryzae expression system has been devel-
oped by Novozymes and used for recombinant protein
production since 1988. Later on Aspergillus niger and
Fusarium venenatum expression systems have been also
developed.
The rationale for entering development of the Aspergillus
oryzae expression system was that we needed an efficient
expression system that could secrete large amounts of pro-
tein at high product purity for production of industrial
enzymes.
The choice of Aspergillus oryzae as the preferred expression
system was made from several different criteria. First of all
Aspergillus oryzae is a well characterized organism that has
been used in the food and fermentation industry in Japan
for several hundred years. This means that the products of
the fungus have been recognized as "Generally Regarded
As Safe" (GRAS). The system was also used by producers
of industrial enzymes using submerged fermentation for
production for decades as Aspergillus oryzae has been used
for production of amylases and proteases since the dawn
of modern enzyme manufacturing. Another important
advantage of Aspergillus oryzae was that it could be geneti-
cally manipulated. Finally there were no patents blocking
the use of Aspergillus oryzae at the time.
Results
The early recombinant strains were essentially wild type
strains transformed with plasmids based on a promoter
and a selection marker that was cloned directly from dif-
ferent Aspergillus strains. Several shortcomings of these
strains were quickly realized and work to improve the sys-
tem was undertaken.
The host strain produced a lot of unwanted proteins such
as amylases, amyloglycosidases and proteases.
In addition to improving the host strain, the expression
vectors have also been improved. In particular the pro-
moter has been the subject of optimization.
The promoter used in the first recombinant Aspergillus
oryzae production strains was the TAKA promoter, the pro-
moter driving the expression of the abundant TAKA amy-
lase. We have characterized this promoter and found a
specific transcription factor called amyR and binding sites
for that transcription factor in the TAKA promoter [1]. The
detailed understanding of the promoter has enabled us to
design new synthetic promoters that are substantially
improved compared to the wild type TAKA promoter.
The improvements of the Aspergillus oryzae expression sys-
tem have resulted in a versatile, clean and high yielding
expression system for enzyme production [2]. With these
improvements the system is suitable for other uses than
just expression of enzymes, including production of bio-
parmaceuticals. So recently we have initiated a number of
projects aiming at developing biopharmaceutical prod-
ucts such as monoclonal antibodies and antimicrobial
peptides [3] using Aspergillus oryzae as expression host.
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